Maria C. Martinez-Riesco - Publications

Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913).

Journal: Nature communications

Published: February 08, 2024

Perioperative Chemotherapy for Liver Metastasis of Colorectal Cancer: Lessons Learned and Future Perspectives.

Journal: Current treatment options in oncology

Published: August 01, 2022

MicroRNA signature and integrative omics analyses define prognostic clusters and key pathways driving prognosis in patients with neuroendocrine neoplasms.

Journal: Molecular oncology

Published: July 27, 2022

Correction to: Chemotherapy in NEN: still has a role?

Journal: Reviews in endocrine & metabolic disorders

Published: July 01, 2022

Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: April 11, 2022

Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors.

Journal: Journal for immunotherapy of cancer

Published: March 01, 2022

Comprehensive Plasma Metabolomic Profile of Patients with Advanced Neuroendocrine Tumors (NETs). Diagnostic and Biological Relevance.

Journal: Cancers

Published: April 29, 2021

Chemotherapy in NEN: still has a role?

Journal: Reviews in endocrine & metabolic disorders

Published: February 23, 2021

Impact of Total Neoadjuvant Therapy vs. Standard Chemoradiotherapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis of Randomized Trials.

Journal: Cancers

Published: October 20, 2020

Cost-effectiveness analysis of selective first-line use of biologics for unresectable RAS wild-type left-sided metastatic colorectal cancer.

Journal: Current oncology (Toronto, Ont.)

Published: November 12, 2019

The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer.

Journal: Expert opinion on drug safety

Published: May 11, 2018

Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer.

Journal: Expert opinion on investigational drugs

Published: October 03, 2017